The Antibody-Drug Conjugate Field

To understand what Hangzhou DAC Biotech does, it helps to understand the technology it serves. Antibody-drug conjugates are a class of targeted cancer therapies that combine three key elements:

• A monoclonal antibody that recognizes and binds to a specific antigen found on the surface of tumor cells
• A cytotoxic payload (a highly potent small-molecule drug) capable of killing cancer cells
• A chemical linker that joins the payload to the antibody and controls when and where the drug is released

The promise of ADCs lies in their precision. Rather than distributing a toxic chemotherapy agent throughout the entire body, an ADC uses the antibody as a homing device to concentrate the cytotoxic payload at the tumor site. This approach has produced several approved therapies and continues to attract significant investment across the pharmaceutical industry.

DAC Biotech operates within this ecosystem by supplying the chemical components and know-how that make ADC construction possible.

Core Business and Capabilities

Hangzhou DAC Biotech's activities center on the design, synthesis, and supply of the specialized molecules used in bioconjugation and ADC development. Its work spans several interconnected areas of chemistry and biology.

Cytotoxic Payloads

A central part of the company's portfolio involves highly potent cytotoxic payloads—the "warhead" molecules that ultimately kill cancer cells once an ADC delivers them. These payloads belong to established and emerging classes of potent anticancer agents, and their synthesis requires specialized facilities and handling procedures because of their extreme potency. DAC Biotech develops and manufactures payload compounds that can be conjugated to antibodies through appropriate linker chemistry.

Linkers and Linker-Payload Constructs

Linkers are the chemical bridges that connect the cytotoxic payload to the antibody. The design of a linker is one of the most important determinants of an ADC's safety and efficacy, because it governs the stability of the conjugate in circulation and the release of the payload inside target cells. DAC Biotech offers a range of linker chemistries, including cleavable and non-cleavable options. The company also produces ready-to-use linker-payload constructs, which combine the linker and payload into a single molecule that drug developers can conjugate directly to their antibody of interest.

Bioconjugation Reagents and Building Blocks

Beyond finished linker-payload assemblies, the company supplies a broad catalog of chemical building blocks and reagents used in bioconjugation. These include functionalized molecules, spacers, protecting groups, and reactive handles that enable chemists to construct custom conjugates. Such reagents support not only antibody-drug conjugates but also other conjugate modalities that rely on site-specific chemical attachment.

Custom Synthesis and Contract Services

In addition to catalog products, Hangzhou DAC Biotech provides custom synthesis services. Drug developers frequently require novel or proprietary molecules that are not available off the shelf. DAC Biotech's chemistry teams can design and synthesize custom payloads, linkers, and linker-payload conjugates to meet specific project requirements. This contract-based work allows the company to serve as a development partner for organizations pursuing unique ADC designs.

Products and Services Summary

The company's offerings can be organized into the following categories:

• Cytotoxic payloads: highly potent anticancer small-molecule agents intended for conjugation to antibodies
• Linkers: cleavable and non-cleavable chemical linkers for controlling payload release
• Linker-payload conjugates: pre-assembled constructs combining linker and payload for direct conjugation
• Bioconjugation reagents: functionalized building blocks, spacers, and reactive intermediates
• PEG-based reagents: polyethylene glycol derivatives used to modify solubility, pharmacokinetics, and conjugation behavior
• Custom synthesis: bespoke design and manufacture of payloads, linkers, and conjugates to customer specifications
• Technical and development support for ADC construction projects

Manufacturing and Quality

Because the compounds DAC Biotech produces are highly potent and destined for pharmaceutical applications, the company emphasizes controlled manufacturing environments and quality standards appropriate to the handling of cytotoxic materials. The synthesis of ADC payloads and linker-payload constructs requires specialized containment, purification, and analytical capabilities. Producing these materials at consistent purity and with well-characterized properties is essential for downstream conjugation and eventual clinical use. DAC Biotech's role as a building-block supplier means its products must meet the rigorous expectations of biopharmaceutical developers.

Customers and Market Position

Hangzhou DAC Biotech serves biotechnology companies, pharmaceutical firms, academic research groups, and contract research and manufacturing organizations that are engaged in the discovery and development of antibody-drug conjugates and related targeted therapeutics. As a company focused specifically on the chemical toolkit for bioconjugation, it fills a niche between broad chemical suppliers and specialized ADC developers.

The global interest in antibody-drug conjugates has expanded substantially, driven by clinical successes and the appeal of targeted delivery in oncology. This has increased demand for the payloads, linkers, and conjugation reagents that companies like DAC Biotech supply. By concentrating on this specialized segment, the company aims to be a reliable source of the essential building blocks that enable ADC innovation.

Significance in the Life Sciences Sector

Companies that supply the fundamental chemical components for advanced therapeutics play an enabling role in the broader drug development landscape. While much public attention focuses on the pharmaceutical companies that bring finished ADC drugs to market, those drugs cannot exist without the payloads, linkers, and conjugation reagents that form their core. Hangzhou DAC Biotech contributes to this value chain by providing the specialized chemistry and manufacturing that underpin ADC research and development.

As part of China's expanding biotechnology and life sciences industry, DAC Biotech also reflects the country's growing capabilities in high-value, specialized chemical synthesis for pharmaceutical applications. Its focus on antibody-drug conjugates aligns with one of the most active and promising areas of modern cancer therapeutics.

Conclusion

Hangzhou DAC Biotech Co., Ltd. is a specialized biotechnology company dedicated to the chemistry that makes antibody-drug conjugates possible. Through its development and supply of cytotoxic payloads, linkers, linker-payload constructs, bioconjugation reagents, and custom synthesis services, the company supports pharmaceutical and biotech developers working at the forefront of targeted cancer therapy. By concentrating on these critical building blocks and offering both catalog products and bespoke chemistry, DAC Biotech serves as a technical partner within the growing global ADC ecosystem.